GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envista Holdings Corp (NYSE:NVST) » Definitions » ROE %

Envista Holdings (Envista Holdings) ROE %

: -20.54% (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Envista Holdings's annualized net income for the quarter that ended in Dec. 2023 was $-870 Mil. Envista Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $4,234 Mil. Therefore, Envista Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was -20.54%.

The historical rank and industry rank for Envista Holdings's ROE % or its related term are showing as below:

NVST' s ROE % Range Over the Past 10 Years
Min: -2.39   Med: 5.2   Max: 8.76
Current: -2.36

During the past 8 years, Envista Holdings's highest ROE % was 8.76%. The lowest was -2.39%. And the median was 5.20%.

NVST's ROE % is ranked worse than
53.25% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: 0.15 vs NVST: -2.36

Envista Holdings ROE % Historical Data

The historical data trend for Envista Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envista Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only 5.20 0.92 8.76 5.88 -2.39

Envista Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.20 4.13 4.83 2.00 -20.54

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Envista Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Envista Holdings ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Envista Holdings's ROE % falls into.



Envista Holdings ROE % Calculation

Envista Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-100.2/( (4206.9+4173.9)/ 2 )
=-100.2/4190.4
=-2.39 %

Envista Holdings's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-869.6/( (4293.2+4173.9)/ 2 )
=-869.6/4233.55
=-20.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Envista Holdings  (NYSE:NVST) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-869.6/4233.55
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-869.6 / 2582.4)*(2582.4 / 6644.45)*(6644.45 / 4233.55)
=Net Margin %*Asset Turnover*Equity Multiplier
=-33.67 %*0.3887*1.5695
=ROA %*Equity Multiplier
=-13.09 %*1.5695
=-20.54 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-869.6/4233.55
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-869.6 / -860) * (-860 / 222) * (222 / 2582.4) * (2582.4 / 6644.45) * (6644.45 / 4233.55)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0112 * -3.8739 * 8.6 % * 0.3887 * 1.5695
=-20.54 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Envista Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Envista Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Envista Holdings (Envista Holdings) Business Description

Traded in Other Exchanges
Address
200 S. Kraemer Boulevard, Building E, Brea, CA, USA, 92821
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments comprising Specialty Products and Technologies and Equipment and Consumables. The Company's Specialty Products & Technologies segment develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. The Company's Equipment & Consumables segment manufactures dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.
Executives
Eric Conley officer: SVP, Orthodontics 200 S. KRAEMER BLVD, BLDG E, BREA CA 92821
Mark E Nance officer: Senior Vice President, GC, Sec 1333 S SPECTRUM BLVD #100, CHANDLER AZ 85286
Stephen Keller officer: Principal Financial Officer 200 S. KRAEMER BLVD., BUILDING E, BREA CA 92821
Amir Aghdaei director, officer: PRESIDENT AND CEO C/O CREDENCE SYSTEMS CORPORATION, 1421 CALIFORNIA CIRCLE, MILPITAS CA 95035
Faez C Kaabi officer: Chief Accounting Officer 200 S. KRAEMER BLVD., BUILDING E, BREA CA 92821
Howard H Yu officer: SENIOR VICE PRESIDENT, CFO 250 S. KRAEMER BLVD., BREA CA 92821
Mischa Reis officer: SENIOR VICE PRESIDENT C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD, BLDG. E, BREA CA 92821
Curt W Bludworth officer: SENIOR VICE PRESIDENT, CHRO 250 S. KRAEMER BLVD., BREA CA 92821
Barbara B. Hulit director C/O FORTIVE CORPORATION, 6920 SEAWAY BLVD, EVERETT WA 98203
Jeffrey Kappler officer: SENIOR VICE PRESIDENT C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD, BLDG. E, BREA CA 92821
Teresa Gayle Sheppard director C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD., BLDG. E, BREA CA 92821
Vivek Jain director ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Jean-claude Kyrillos officer: Senior Vice President C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD., BLDG. E, BREA CA 92821
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
William K Daniel director 2135 WEST MAPLE ROAD, TROY MI 48084